insights_auto
FARN 주가가 상승한 이유: 2.05%?
자세히 알아보기chevron_right
FARN:LON
Faron Pharmaceuticals Oy
GBX 37.25
arrow_upward
+2.05%(+0.75) 1D
10월 2일, 오후 4시 30분 0초 GMT+1 · GBX
search
모든 종목 코드
| 종목 코드 | 가격 | 변동 | 변동률(%) |
|---|
insights_autoFARN의 주요 통계 생성 중...
시가
GBX 38.00
고가
GBX 38.00
저가
GBX 35.09
시가총액
7389.60만
평균 거래량
5.14만
거래량
3.60만
52주 최고가
GBX 193.58
52주 최저가
GBX 34.00
EPS
-GBX 0.10
유통 주식수
3102.79만
직원 수
36
시가
GBX 38.00
고가
GBX 38.00
저가
GBX 35.09
시가총액
7389.60만
평균 거래량
5.14만
거래량
3.60만
52주 최고가
GBX 193.58
52주 최저가
GBX 34.00
EPS
-GBX 0.10
유통 주식수
3102.79만
직원 수
36
뉴스 기사
웹 소스 및 뉴스 파트너 제공
프로필
Faron Pharmaceuticals is a Finnish drug discovery and development company based in Turku, Finland.
The company was founded in 2003 by a group led by Markku Jalkanen, who now acts as the company's Chief Executive Officer. It specialises in the development of treatments for acute organ traumas, vascular damage and cancer immunotherapy.
Its lead product Traumakine has been developed to treat acute respiratory distress syndrome. It is currently undergoing international phase III clinical trials after an open-label, early-phase trial showed promising results in the treatment patients with ARDS. The drug is known to function by enhancing lung CD73 expression and increasing production of anti-inflammatory adenosine, such that vascular leaking and escalation of inflammation are reduced. The U.S. Food and Drug Administration FDA has accepted the proposed protocol design for the next Traumakine study in March 2020. The phase III study is a comparison of efficacy in the treatment of patients with ARDS.
In 2020 Traumakine was selected to take part in the WHO Solidarity trial and REMAP-CAP trials to find drugs for the symptoms of Covid_19. Wikipedia
Faron Pharmaceuticals Oy에 관한 정보